Telisotuzumab vedotin shows promising results in asian patients with c-Met overexpressing NSCLC

The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing, epidermal growth factor receptor (EGFR) wildtype (WT), locally advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC), according to research presented today at the International Association for the Study of Lung Cancer’s 2024 World Conference on Lung Cancer.

Chime, Leads and Beigene enter antibody development deal

The Phase I trial data demonstrated the enhanced anti-tumour activity of LBL-007 in individuals with later-stage solid tumours. Credit: National Cancer Institute on Unsplash. Chime

July 3, 2023

ALTO-100 by Alto Neuroscience for Post-Traumatic Stress Disorder (PTSD): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

November 5, 2023

Study suggests mosquitoes as potential vectors for Buruli ulcers in Australia

Researchers find strong evidence suggesting mosquitoes may transmit Mycobacterium ulcerans, the bacteria causing Buruli ulcers, but caution that further study is needed.

August 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.